Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728259 · ClinicalTrials.gov registry record · Phase 1
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
A Phase 1 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01728259 is a Phase 1 study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 18 participants.
The verdict
NCT01728259, a Phase 1 study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop abnormal cells from growing. Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide and bortezomib together with dexamethasone may be an effective treatment for amyloid light-chain amyloidosis or light chain deposition disease
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG dexamethasone
- DRUG pomalidomide
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-03 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01728259
The ClinicalTrials.gov registry entry for NCT01728259 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01728259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01728259 about?
NCT01728259 is a clinical study titled "First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD". This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate the immune system in ...
What is the current status of trial NCT01728259?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-03. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT01728259?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), dexamethasone (DRUG), pomalidomide (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT01728259?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.